SynthesisRheumatology international2023
Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis.
Synthesis in Rheumatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab.Arthritis & rheumatology (Hoboken, N.J.) · 2026Trial
- Real-World Concordance of Indirect Immunofluorescence and Antigen-Specific Assays in Antineutrophil Cytoplasmic Antibody Testing: A Retrospective High-Volume Laboratory Study.The Eurasian journal of medicine · 2026Article
- Inflammatory blood count ratios discriminate disease activity and remain persistently elevated during glucocorticoid-free remission in ANCA-associated vasculitis.Clinical and experimental medicine · 2026Article
- Systematic Review of Kidney Injury Biomarkers for the Evaluation of CKD of Uncertain Etiology.Kidney international reports · 2024Article
- Granulomatosis With Polyangiitis and Concomitant Superinfection: A Defying Diagnosis and Management Approach.Cureus · 2024Article
- Recent updates in enthesitis-related arthritis.Rheumatology international · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapse in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) is associated with significant morbidity and mortality. Utility of ANCA for prediction of relapses is still controversial. PubMed/MEDLINE, Scopus, and WebOfScience were searched, screened and confirmed for inclusion [PROSPERO No: CRD42020220308]. Studies measuring serial ANCA by ELISA or indirect immunofluorescence (IF), reporting relapses with sufficient data to calculate sensitivity and specificity were included. Diagnostic odds ratio (OR), sensitivity, specificity and likelihood ratios (LR) were synthesized using a bivariate mixed-effect regression model. Sub-group analysis included a comparison between ELISA and IIF, anti-myeloperoxidase (MPO) and -proteinase 3(PR3), and type of rise in ANCA. For meta-analysis of survival outcomes, hazard ratios were synthesized using a random-effect model. QUADAS-2 was used for assessing quality of studies, I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.